<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910217</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-Lokowalkers-2021</org_study_id>
    <nct_id>NCT04910217</nct_id>
  </id_info>
  <brief_title>Robot-Assisted Gait Therapy in the Subacute Phase of First Ischemic Stroke</brief_title>
  <official_title>Robot-Assisted Gait Therapy in the Subacute Phase of First Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VSB - Technical University of Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Robot-assisted gait training (RAGT) represents a modern concept of neurorehabilitation in&#xD;
      stroke patients. This single-center randomized parallel-group neurorehabilitation trial with&#xD;
      blinded primary outcome assessment is aimed at patients after the first-ever ischaemic stroke&#xD;
      in the anterior or posterior cerebral circulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim is to determine, whether the RAGT by using the Lokomat exoskeleton device&#xD;
      (Hoccoma, Switzerland) plus the protocol-defined conventional rehabilitation versus&#xD;
      conventional rehabilitation with the ability to use the leg/lower body exercisers device,&#xD;
      improves the gait of post-stroke patients after 6 months. Both groups are treated with the&#xD;
      protocol-defined rehabilitation (ergotherapy and physiotherapy) for 60 min 5 times a week, a&#xD;
      total of 15 times within 3 weeks (a total of 1200 min). The Lokowalkers group undergoes the&#xD;
      RAGT using the Lokomat Pro Freed device for 20-50 minutes 5 times a week for a total of 15&#xD;
      times for 3 weeks (a total of 1800 minutes). The primary endpoint is the Functional&#xD;
      Ambulation Category (FAC) after 6 months. Secondary endpoints include Functional Independence&#xD;
      Measure (FIM) after 15th therapy and after 6 months, FAC (after 15th therapy and after 3&#xD;
      months), 3. 10-meter walk test (10MWT) (after 15th therapy, after 3 and 6 months), 4. Timed&#xD;
      Up and Go Test (TUG) (after 15th therapy, after 3 and 6 months, 3- and 6- months modified&#xD;
      Rankin Scale (mRS), Berg Balance Scale (BBS, after 15th therapy, after 3 and 6 months), and&#xD;
      36-Item Short Form Survey (SF-36, after 3 and 6 months). Magnetic resonance imaging (MRI)&#xD;
      sub-study will objectify the natural development of ischemic brain lesions and the evolution&#xD;
      of post-stroke brain atrophy within the 12-months of neuroimaging follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-centre randomized parallel group neurorehabilitation trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Ambulation Category (FAC) at 6-months</measure>
    <time_frame>6 months</time_frame>
    <description>Functional Ambulation Category (FAC) - the scale range is from 0 to 5. The value at 6-months will be observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Independence Measure (FIM) after 3 weeks and after 6 months</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>FIM is an 18-item measurement tool that explores an individual's physical, psychological and social functions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ambulation Category (FAC) (after 3 weeks and after 3 months)</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Functional Ambulation Category (FAC) - the scale range is from 0 to 5. The value after 15th therapy and after 3 months will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-meter walk test (10-MWT) (after 3 weeks, after 3 and 6 months)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>10-meter walk test will be performed after 3 weeks, after 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go Test (TUG) (after 3 weeks, after 3 and 6 months)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Timed Up and Go Test (TUG) will be performed after 3 weeks, after 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3- and 6- months modified Rankin Scale (mRS)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>3- and 6- months modified Rankin Scale (mRS) assesses the functional independence and represents a standard outcome measure in post-stroke patients (range from 0 to 6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Scale (BBS, after 3 weeks, after 3 and 6 months)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Berg Balance Scale (BBS) objectifies balance functions in 14 tasks. It assesses the risk of possible falls: 0-20 high, 21-40 medium, 41-56 low risk of falling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Survey (SF-36, after 3 and 6 months)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>(SF-36) is an oft-used, self-reported measure of health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The number and character of adverse effects will be observed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early termination of the study</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The number of patients terminating the study early will be observed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason/s for the termination</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The reason/s for the termination will be observed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study-related death or death unrelated to study</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The number of study-related deaths or deaths unrelated to study will be observed during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Lokomat intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized into the Lokomat arm will undergo therapy with Lokomat Pro FreeD for 20-50 minutes 5-times a week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leg/lower body exerciser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will undergo therapy with leg/lower body exerciser for 20-50 minutes, 5 times per week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional rehabilitation</intervention_name>
    <description>Patients will undergo conventional rehabilitation</description>
    <arm_group_label>Leg/lower body exerciser</arm_group_label>
    <arm_group_label>Lokomat intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leg/lower body exerciser device intervention.</intervention_name>
    <description>Patients will undergo leg/lower body exerciser device therapy.</description>
    <arm_group_label>Leg/lower body exerciser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lokomat intervention</intervention_name>
    <description>Patients will undergo therapy with Lokomat Pro FreeD device intervention.</description>
    <arm_group_label>Lokomat intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent by the participant or legal representative&#xD;
&#xD;
          -  interval between stroke and first rehabilitation session &lt; 6 weeks (study target&#xD;
             within 2 weeks)&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  early modified Rankin scale (mRS) 2 to 4 (pre-stroke mRS 0 to 1)&#xD;
&#xD;
          -  early FAC of 0 to 3 (pre-stroke FAC of 5)&#xD;
&#xD;
          -  standing ability with support up to 3 minutes and vertical tolerance &gt; 15 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability or refusal to sign an informed consent&#xD;
&#xD;
          -  history of stroke or another brain disease (tumour, multiple sclerosis, brain or&#xD;
             spinal cord injury)&#xD;
&#xD;
          -  severe internal, oncological, or surgical comorbidity preventing long-term&#xD;
             re-habilitation or causing chronic or progressive gait disorder&#xD;
&#xD;
          -  limited collaboration of any reason, moderate or severe dementia assessed by using the&#xD;
             Montreal Cognitive Assessment (MoCA) scale&#xD;
&#xD;
          -  impaired skin integrity in the lower torso and limbs preventing the use of Lokomat&#xD;
             device&#xD;
&#xD;
          -  limitations given by the Lokomat exoskeleton device (weight &gt; 135 kg, thigh-length&#xD;
             23-35 cm, shank length 35-47cm)&#xD;
&#xD;
          -  limitations given by the leg/lower body exerciser (weight &gt; 180 kg, height &lt; 120 cm or&#xD;
             &gt; 200 cm, (sub)acute lower limb fractures, deep vein thrombosis, skin disintegration)&#xD;
&#xD;
          -  any contraindication to perform brain MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ondřej Volný, MD,PhD,FESO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Ondrej Volny, MD,PhD,FESO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iva Fiedorova, MSc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavla Hanzlíkova, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Bar, Assoc.Prof.,MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Roubec, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radim Licenik, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miloslav Klugar, Dr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jitka Klugarova, Dr, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Pokorna, prof.,Dr,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dana Salounova, prof.,Ing.,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Elias, prof.,MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina Chmelova, MD,PhD,MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Mikulik, prof.,MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Brodova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Mehrholz J, Wagner K, Rutte K, Meissner D, Pohl M. Predictive validity and responsiveness of the functional ambulation category in hemiparetic patients after stroke. Arch Phys Med Rehabil. 2007 Oct;88(10):1314-9.</citation>
    <PMID>17908575</PMID>
  </reference>
  <reference>
    <citation>Albert SJ, Kesselring J. Neurorehabilitation of stroke. J Neurol. 2012 May;259(5):817-32. doi: 10.1007/s00415-011-6247-y. Epub 2011 Oct 1. Review.</citation>
    <PMID>21964750</PMID>
  </reference>
  <reference>
    <citation>Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, Deruyter F, Eng JJ, Fisher B, Harvey RL, Lang CE, MacKay-Lyons M, Ottenbacher KJ, Pugh S, Reeves MJ, Richards LG, Stiers W, Zorowitz RD; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016 Jun;47(6):e98-e169. doi: 10.1161/STR.0000000000000098. Epub 2016 May 4. Review. Erratum in: Stroke. 2017 Feb;48(2):e78. Stroke. 2017 Dec;48(12 ):e369.</citation>
    <PMID>27145936</PMID>
  </reference>
  <reference>
    <citation>Maier M, Ballester BR, Verschure PFMJ. Principles of Neurorehabilitation After Stroke Based on Motor Learning and Brain Plasticity Mechanisms. Front Syst Neurosci. 2019 Dec 17;13:74. doi: 10.3389/fnsys.2019.00074. eCollection 2019. Review.</citation>
    <PMID>31920570</PMID>
  </reference>
  <reference>
    <citation>Morone G, Paolucci S, Cherubini A, De Angelis D, Venturiero V, Coiro P, Iosa M. Robot-assisted gait training for stroke patients: current state of the art and perspectives of robotics. Neuropsychiatr Dis Treat. 2017 May 15;13:1303-1311. doi: 10.2147/NDT.S114102. eCollection 2017. Review.</citation>
    <PMID>28553117</PMID>
  </reference>
  <reference>
    <citation>Moucheboeuf G, Griffier R, Gasq D, Glize B, Bouyer L, Dehail P, Cassoudesalle H. Effects of robotic gait training after stroke: A meta-analysis. Ann Phys Rehabil Med. 2020 Nov;63(6):518-534. doi: 10.1016/j.rehab.2020.02.008. Epub 2020 Mar 27.</citation>
    <PMID>32229177</PMID>
  </reference>
  <reference>
    <citation>Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS. Recovery of walking function in stroke patients: the Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995 Jan;76(1):27-32.</citation>
    <PMID>7811170</PMID>
  </reference>
  <reference>
    <citation>Bruni MF, Melegari C, De Cola MC, Bramanti A, Bramanti P, Calabrò RS. What does best evidence tell us about robotic gait rehabilitation in stroke patients: A systematic review and meta-analysis. J Clin Neurosci. 2018 Feb;48:11-17. doi: 10.1016/j.jocn.2017.10.048. Epub 2017 Dec 6. Review.</citation>
    <PMID>29208476</PMID>
  </reference>
  <reference>
    <citation>Kim MS, Kim SH, Noh SE, Bang HJ, Lee KM. Robotic-Assisted Shoulder Rehabilitation Therapy Effectively Improved Poststroke Hemiplegic Shoulder Pain: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2019 Jun;100(6):1015-1022. doi: 10.1016/j.apmr.2019.02.003. Epub 2019 Mar 13.</citation>
    <PMID>30878496</PMID>
  </reference>
  <reference>
    <citation>Mehrholz J, Thomas S, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for walking after stroke. Cochrane Database Syst Rev. 2020 Oct 22;10:CD006185. doi: 10.1002/14651858.CD006185.pub5.</citation>
    <PMID>33091160</PMID>
  </reference>
  <reference>
    <citation>Zaidi SF, Aghaebrahim A, Urra X, Jumaa MA, Jankowitz B, Hammer M, Nogueira R, Horowitz M, Reddy V, Jovin TG. Final infarct volume is a stronger predictor of outcome than recanalization in patients with proximal middle cerebral artery occlusion treated with endovascular therapy. Stroke. 2012 Dec;43(12):3238-44. doi: 10.1161/STROKEAHA.112.671594. Epub 2012 Nov 15.</citation>
    <PMID>23160876</PMID>
  </reference>
  <reference>
    <citation>Bucker A, Boers AM, Bot JCJ, Berkhemer OA, Lingsma HF, Yoo AJ, van Zwam WH, van Oostenbrugge RJ, van der Lugt A, Dippel DWJ, Roos YBWEM, Majoie CBLM, Marquering HA; MR CLEAN Trial Investigators (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Associations of Ischemic Lesion Volume With Functional Outcome in Patients With Acute Ischemic Stroke: 24-Hour Versus 1-Week Imaging. Stroke. 2017 May;48(5):1233-1240. doi: 10.1161/STROKEAHA.116.015156. Epub 2017 Mar 28.</citation>
    <PMID>28351963</PMID>
  </reference>
  <reference>
    <citation>Aurich-Schuler T, Gut A, Labruyère R. The FreeD module for the Lokomat facilitates a physiological movement pattern in healthy people - a proof of concept study. J Neuroeng Rehabil. 2019 Feb 6;16(1):26. doi: 10.1186/s12984-019-0496-x. Erratum in: J Neuroeng Rehabil. 2019 Jun 11;16(1):74.</citation>
    <PMID>30728040</PMID>
  </reference>
  <reference>
    <citation>Bower K, Thilarajah S, Pua YH, Williams G, Tan D, Mentiplay B, Denehy L, Clark R. Dynamic balance and instrumented gait variables are independent predictors of falls following stroke. J Neuroeng Rehabil. 2019 Jan 7;16(1):3. doi: 10.1186/s12984-018-0478-4.</citation>
    <PMID>30612584</PMID>
  </reference>
  <reference>
    <citation>Heinemann AW, Linacre JM, Wright BD, Hamilton BB, Granger C. Relationships between impairment and physical disability as measured by the functional independence measure. Arch Phys Med Rehabil. 1993 Jun;74(6):566-73.</citation>
    <PMID>8503745</PMID>
  </reference>
  <reference>
    <citation>Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. Measuring balance in the elderly: validation of an instrument. Can J Public Health. 1992 Jul-Aug;83 Suppl 2:S7-11.</citation>
    <PMID>1468055</PMID>
  </reference>
  <reference>
    <citation>Anderson C, Laubscher S, Burns R. Validation of the Short Form 36 (SF-36) health survey questionnaire among stroke patients. Stroke. 1996 Oct;27(10):1812-6.</citation>
    <PMID>8841336</PMID>
  </reference>
  <reference>
    <citation>Park IJ, Park JH, Seong HY, You JSH, Kim SJ, Min JH, Ko HY, Shin YI. Comparative Effects of Different Assistance Force During Robot-Assisted Gait Training on Locomotor Functions in Patients With Subacute Stroke: An Assessor-Blind, Randomized Controlled Trial. Am J Phys Med Rehabil. 2019 Jan;98(1):58-64. doi: 10.1097/PHM.0000000000001027.</citation>
    <PMID>30142092</PMID>
  </reference>
  <reference>
    <citation>Barca C, Foray C, Hermann S, Döring C, Schäfers M, Jacobs AH, Zinnhardt B. Characterization of the inflammatory post-ischemic tissue by full volumetric analysis of a multimodal imaging dataset. Neuroimage. 2020 Nov 15;222:117217. doi: 10.1016/j.neuroimage.2020.117217. Epub 2020 Jul 31.</citation>
    <PMID>32745676</PMID>
  </reference>
  <reference>
    <citation>Baudat C, Maréchal B, Corredor-Jerez R, Kober T, Meuli R, Hagmann P, Michel P, Maeder P, Dunet V. Automated MRI-based volumetry of basal ganglia and thalamus at the chronic phase of cortical stroke. Neuroradiology. 2020 Nov;62(11):1371-1380. doi: 10.1007/s00234-020-02477-x. Epub 2020 Jun 17.</citation>
    <PMID>32556424</PMID>
  </reference>
  <reference>
    <citation>Bernarding J, Braun J, Hohmann J, Mansmann U, Hoehn-Berlage M, Stapf C, Wolf KJ, Tolxdorff T. Histogram-based characterization of healthy and ischemic brain tissues using multiparametric MR imaging including apparent diffusion coefficient maps and relaxometry. Magn Reson Med. 2000 Jan;43(1):52-61.</citation>
    <PMID>10642731</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gait</keyword>
  <keyword>stroke</keyword>
  <keyword>robotic rehabilitation</keyword>
  <keyword>exoskeleton</keyword>
  <keyword>neurorehabilitation</keyword>
  <keyword>Lokomat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

